| 產品編號 | bs-12920R-PE |
| 英文名稱1 | Rabbit Anti-phospho-Cytokeratin 8 (Ser431)/PE Conjugated antibody |
| 中文名稱 | PE標記的磷酸化細胞角蛋白8抗體 |
| 別 名 | Cytokeratin 8 (phospho S431); p-Cytokeratin 8 (phospho S431); card2; Cardiac autoantigen 2 120kD; CK 8; CK-8; ck8; Cyk 8; cyk8; CYKER; Cytokeratin endo A; Cytokeratin-8; Cytokeratin8; DreK8; EndoA; k0; CYK8; k2c8; K2C8_HUMAN; k8; Keratin 8; Keratin type ii cytoskeletal 8; Keratin, type II cytoskeletal 8; Keratin-8; Keratin8; KO; Krt 2.8; Krt 8; krt8; KRT-8; MGC118110; MGC174782; MGC53564; MGC85764; sb:cb186; Type-II keratin Kb8. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 產品類型 | 磷酸化抗體 |
| 研究領域 | 腫瘤 細胞生物 免疫學 信號轉導 細胞類型標志物 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, Mouse, (predicted: Rat, Horse, ) |
| 產品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 53kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human CK8 around the phosphorylation site of Ser431 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: This gene is a member of the type II keratin family clustered on the long arm of chromosome 12. Type I and type II keratins heteropolymerize to form intermediate-sized filaments in the cytoplasm of epithelial cells. The product of this gene typically dimerizes with keratin 18 to form an intermediate filament in simple single-layered epithelial cells. This protein plays a role in maintaining cellular structural integrity and also functions in signal transduction and cellular differentiation. Mutations in this gene cause cryptogenic cirrhosis. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jan 2012]. Function: Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle. Subunit: Heterotetramer of two type I and two type II keratins. KRT8 associates with KRT18. Associates with KRT20. Interacts with HCV core protein and PNN. When associated with KRT19, interacts with DMD. Interacts with TCHP. Interacts with APEX1. Subcellular Location: Cytoplasm. Nucleus, nucleoplasm. Nucleus matrix. Tissue Specificity: Observed in muscle fibers accumulating in the costameres of myoplasm at the sarcolemma membrane in structures that contain dystrophin and spectrin. Expressed in gingival mucosa and hard palate of the oral cavity. Post-translational modifications: Phosphorylation on serine residues is enhanced during EGF stimulation and mitosis. Ser-74 phosphorylation plays an important role in keratin filament reorganization. O-glycosylated. O-GlcNAcylation at multiple sites increases solubility, and decreases stability by inducing proteasomal degradation. O-glycosylated (O-GlcNAcylated), in a cell cycle-dependent manner. DISEASE: Defects in KRT8 are a cause of cirrhosis (CIRRH) [MIM:215600]. Similarity: Belongs to the intermediate filament family. Database links: Entrez Gene: 3856 Human Entrez Gene: 16691 Mouse Omim: 148060 Human SwissProt: P05787 Human SwissProt: P11679 Mouse Unigene: 533782 Human Unigene: 708445 Human Unigene: 358618 Mouse Unigene: 11083 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 細胞角蛋白是一類與結構相關的蛋白家族，其在上皮細胞中形成細胞骨架中間絲。CK8存在于某些正常腺上皮及其腫瘤，包括許多導管上皮和腺上皮，如結腸、胃、小腸、氣管的上皮和尿路上皮。CK8主要用于腺癌和導管癌的診斷，該抗體特異識別第23位絲氨酸磷酸化的CK8。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
